The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England and the Welsh Government. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This short report details the top-level findings for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. The top-level findings below, along with supporting data at Clinical Commissioning Group (CCG), Local Health Board (LHB), GP practice and specialist diabetes service have been made available to provide data back to services in a timely manner that can help drive improvements in the quality of diabetes care locally. The full report, scheduled for 2020, will contain full key findings, recommendations and results of new analyses into HbA1c check frequencies and blood glucose drug cohorts. We will communicate to users when the date for this report has been finalised. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This report details the findings for the 2017-18 audit. The audit collected data during May and June 2018, for the period 01 January 2017 to 31 March 2018 and contains the full key findings, recommendations and new analysis relating to cardiovascular disease (CVD) risk, including new treatment targets showing statin prescriptions for CVD risk reduction. This report follows the NDA short report publication in November 2018, which provided the top level findings for the 2017-18 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally.

The information available from this webpage comes from the National Diabetes Audit - Diabetes Prevention Programme report. The NHS Diabetes Prevention Programme (NHS DPP) is a joint commitment from NHS England, Public Health England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia. This report uses data collected alongside the National Diabetes Audit (NDA) for the period January 2017 to March 2018 inclusive. This report is for England only. Unlike the NDA, it does not include information on Wales. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Audit - Diabetes Prevention Programme data for 2017-18 is available at England, Clinical Commissioning Group (CCG) and GP practice-level for:

The National Diabetes Insulin Pump Audit is part of the National Diabetes Audit (NDA).

The National Diabetes Insulin Pump Audit collects information on the number and characteristics of people with Type 1 diabetes using an insulin pump, the reasons for going on an insulin pump and the outcomes achieved since starting on the pump.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Insulin Pump Audit data for 2017-18 is available at England and Wales, Local Health Board (LHB) and Specialist Diabetes Service level for:

• Participation
• Patient demographics
• Prevalence
• Care process completion
• Treatment targets
• Diabetes characteristics

Using and interpreting the data

Data from the National Diabetes Insulin Pump Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Local Health Boards and Specialist Diabetes Services are identified by organisation code.

What does the data cover?

The audit looks at the following areas:

• Reason for starting on an insulin pump
• Care processes
• Treatment targets
• Structured Education

What period does the data cover?

This data covers the top level findings from the 2017-18 National Diabetes Insulin Pump Audit for the period 1 January 2017 to 31 March 2018. This National Report was published on 8 August 2019.

The National Diabetes Inpatient Audit (NaDIA) measures the quality of diabetes care provided to people with diabetes while they are admitted to hospital whatever the cause, and aims to support quality improvement. Data is collected and submitted by hospital staff in England and Wales. The NaDIA audit is part of the National Diabetes Audit (NDA) portfolio within the National Clinical Audit and Patient Outcomes Programme (NCAPOP), commissioned by the Healthcare Quality Improvement Partnership (HQIP). In September 2018 NaDIA undertook a snapshot audit of hospital characteristics in England and Wales. In addition to the snapshot audit the collection of NaDIA-Harms began in England in 2018; this is a new continuous collection of serious inpatient harms that only affect people with diabetes. The NaDIA-Harms 2018 report can be found here - http://digital.nhs.uk/pubs/nadia2018

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales and measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Audit data for 2017-18 is available at England and Wales, Clinical Commissioning Group (CCG), Local Health Board (LHB), English GP practice and Specialist Diabetes Service level for:

• Participation
• Patient demographics
• Diabetes characteristics
• Structured Education offers

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. GP practices and CCGs/LHBs are identified by organisation code.

What does the data cover?

The audit looks at the following areas:

• Care processes
• Treatment targets
• Structured Education

What period does the data cover?

This data covers the top level findings from the 2017-18 National Diabetes Audit for the period 1 January 2017 to 31 March 2018. This National Report was published on 13 June 2019.

The National Diabetes Insulin Pump Audit is part of the National Diabetes Audit (NDA).

The National Diabetes Insulin Pump Audit collects information on the number and characteristics of people with Type 1 diabetes using an insulin pump, the reasons for going on an insulin pump and the outcomes achieved since starting on the pump.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Insulin Pump Audit data for 2016-17 is available at England and Wales, Local Health Board (LHB) and Specialist Diabetes Service level for:

• Participation
• Patient demographics
• Prevalence
• Care process completion
• Treatment targets
• Diabetes characteristics

Using and interpreting the data

Data from the National Diabetes Insulin Pump Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Local Health Boards and Specialist Diabetes Services are identified by organisation code.

What does the data cover?

The audit looks at the following areas:

• Reason for starting on an insulin pump
• Care processes
• Treatment targets
• Structured Education

What period does the data cover?

This data covers the top level findings from the 2016-17 National Diabetes Insulin Pump Audit for the period 1 January 2016 to 31 March 2017. This National Report was published on 14 June 2018.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. During September and October 2018, hospitals across England and Wales collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. 2018 was a designated NaDIA Quality Improvement Collaborative (QIC) year. To reduce the burden on QIC participants, the NaDIA 2018 collection undertook the Hospital Characteristics (HC) survey only. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Inpatient Audit data for 2018 is available at hospital site level for: Audit participation Measures of staffing levels and care improvement initiatives. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code. What does the data cover? The audit looks at the following areas: * Participation in the audit * Inpatient staffing levels * Take-up of care improvement initiatives What period does the data cover? This report covers hospital characteristics during September and October 2018. The audit report was published on 9 May 2019. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. During September and October 2018, hospitals across England and Wales collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. 2018 was a designated NaDIA Quality Improvement Collaborative (QIC) year. To reduce the burden on QIC participants, the NaDIA 2018 collection undertook the Hospital Characteristics (HC) survey only. # Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. # What information is being made available? National Diabetes Inpatient Audit data for 2018 is available at hospital site level for: * Audit participation * Measures of staffing levels and care improvement initiatives. These data do not list individual patient information nor do they contain any patient identifiable data. # Using and interpreting the data Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care. # Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code. # What does the data cover? The audit looks at the following areas: * Participation in the audit * Inpatient staffing levels * Take-up of care improvement initiatives # What period does the data cover? This report covers hospital characteristics during September and October 2018. The audit report was published on 9 May 2019. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

NaDIA-Harms is a mandatory year-round collection of four harms that can occur to diabetic inpatients in Acute hospitals in England. The objective of NaDIA Harms is to help reduce the rates of serious inpatient harms by collecting and providing case mix adjusted benchmarked feedback to hospital trusts to inform quality improvement work. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Inpatient Audit – Harms data for 2018 is available at national level for: Audit participation The number of harms These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Inpatient Audit – Harms should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit - Harms will be made available in CSV format. What period does the data cover? The report covers impatient harms between May and October 2018. The audit report was published on 9 May 2019.

The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA) and is managed by NHS Digital under an agreement with the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh Government. The NDA is delivered by NHS Digital, in partnership with Diabetes UK and the National Cardiovascular Intelligence Network (part of Public Health England). Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Pregnancy in Diabetes Audit data for 2018 is available at England and Wales, Region and Provider level for:

The information available from this webpage comes from the National Diabetes Inpatient Safety Audit (NDISA). The NDISA measures the frequency of avoidable diabetic harms. The NDISA audit is part of the National Diabetes Audit (NDA) programme commissioned by the Healthcare Quality Improvement Partnership (HQIP) and managed by NHS England, in collaboration with Diabetes UK. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme (NCAPOP). What information is being made available? NDISA data for 2018-2021 covers the provision of inpatient services in England and Wales and diabetes-specific inpatient harms in England. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from NDISA should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. For each NDISA report, a data file will be made available in CSV format. What period does the data cover? The NDISA 2018-2021 report covers: the provision of inpatient services in England and Wales on 1 October 2021; and diabetes-specific inpatient harms in England between May 2018 and October 2021. The report was published on 14 July 2022.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

This series contains publications from the National Diabetes Core Audit. The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales.

The National Diabetes Foot Care Audit (NDFA) is a continuous audit of diabetic foot disease in England and Wales. The audit enables all diabetes foot care services to measure their performance against NICE clinical guidelines and peer units, and to monitor adverse outcomes for people with diabetes who develop diabetic foot disease.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

Aggregated National Diabetes Foot Care Audit (NDFA) data for 2015-18 at NHS trust, specialist foot care service, sustainability and transformation partnership (STP), and clinical commissioning group (CCG) level.

Measures about the process of care given to patients

Information about care outcomes and treatment.

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Foot Care Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Foot Care Audit will be made available in CSV format. Trusts and CCGs are identified by name and national code. Foot care services and STPs are identified by name and locally derived code.

What does the data cover?

The audit looks at the following areas:

• Structures: are the nationally recommended care structures in place for the management of diabetic foot disease?

• Processes: does the treatment of active diabetic foot disease comply with nationally recommended guidance?

• Outcomes: are the outcomes of diabetic foot disease optimised?

What period does the data cover?

This data covers patients first seen with a diabetic foot ulcer by a specialist foot service between 1 April 2015 and 31 March 2018. This National Report was published on 9 May 2019.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

The National Diabetes Foot Care Audit (NDFA) is a continuous audit of diabetic foot disease in England and Wales. The audit enables all diabetes foot care services to measure their performance against NICE clinical guidelines and peer units, and to monitor adverse outcomes for people with diabetes who develop diabetic foot disease.

What information is being made available? 

Trust, service, sustainability and transformation partnership (STP), and clinical commissioning group (CCG) audit participation and data completeness for the key fields

Measures about the process of care given to patients 

Information about care outcomes and treatment.

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Foot Care Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Foot Care Audit will be made available in CSV format. Trusts and CCGs are identified by name and national code. Foot care services and STPs are identified by name and locally derived code.

What does the data cover?

The audit looks at the following areas:

Structures: are the nationally recommended care structures in place for the management of diabetic foot disease?

Processes: does the treatment of active diabetic foot disease comply with nationally recommended guidance?

Outcomes: are the outcomes of diabetic foot disease optimised?

What period does the data cover?

This data covers patients first seen with a diabetic foot ulcer by a specialist foot team between 14 July 2014 and 31 March 2017. This National Report was published on 14 March 2018.

ObjectivesHealth administrative data are frequently used for diabetes surveillance. We aimed to determine the sensitivity and specificity of a commonly-used diabetes case definition (two physician claims or one hospital discharge abstract record within a two-year period) and their potential effect on prevalence estimation.MethodsFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched Medline (from 1950) and Embase (from 1980) databases for validation studies through August 2012 (keywords: “diabetes mellitus”; “administrative databases”; “validation studies”). Reviewers abstracted data with standardized forms and assessed quality using Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria. A generalized linear model approach to random-effects bivariate regression meta-analysis was used to pool sensitivity and specificity estimates. We applied correction factors derived from pooled sensitivity and specificity estimates to prevalence estimates from national surveillance reports and projected prevalence estimates over 10 years (to 2018).ResultsThe search strategy identified 1423 abstracts among which 11 studies were deemed relevant and reviewed; 6 of these reported sensitivity and specificity allowing pooling in a meta-analysis. Compared to surveys or medical records, sensitivity was 82.3% (95%CI 75.8, 87.4) and specificity was 97.9% (95%CI 96.5, 98.8). The diabetes case definition underestimated prevalence when it was ≤10.6% and overestimated prevalence otherwise.ConclusionThe diabetes case definition examined misses up to one fifth of diabetes cases and wrongly identifies diabetes in approximately 2% of the population. This may be sufficiently sensitive and specific for surveillance purposes, in particular monitoring prevalence trends. Applying correction factors to adjust prevalence estimates from this definition may be helpful to increase accuracy of estimates.

The excel file contains unit, regional and national level data obtained from the National Paediatric Diabetes Audit 2018-2019. Specifically, it includes information on patient characteristics, completion of health checks and outcomes achieved (as recommended by the National Institute for Clinical Excellence) for infants, children and young people with type 1 diabetes, under the age of 25, who attended paediatric diabetes units in England and Wales between 1 April 2018 and the 31 March 2019. Data are included for the seven key health checks: • Glycated Haemoglobin A1c (HbA1c) • Body Mass Index (BMI) • Thyroid • Blood pressure • Urinary albumin • Foot examination • Eye screening. Data on other health checks include: • Psychological assessment • Offering of immunisation against influenza • Advice about managing diabetes (‘sick-day rules’) • Using (or trained to use) blood ketone testing strips and a meter • Cholesterol • Additional dietetic support Data are included for health checks at diagnosis • Screening for autoimmune disease (coeliac and thyroid disease) • Provision of Level 3 carbohydrate-counting education Data on outcomes of care include: • HbA1c target measurements • Small vessel (microvascular) disease • Large vessel (macrovascular) disease • Autoimmune disease (coeliac and thyroid disease) The data were first published in 2020 alongside the National Paediatric Diabetes Audit Report 2018-2019 Data suppressed due to small numbers (<5). For further information and details on the audit please refer to: • National Paediatric Diabetes Audit Annual Reports: https://www.rcpch.ac.uk/resources/npda-annual-reports • NPDA results online: http://npda-results.rcpch.ac.uk/default.aspx • The RCPCH website: https://www.rcpch.ac.uk/npda

The excel file contains unit, regional and national level data obtained from the National Paediatric Diabetes Audit 2018-2019. Specifically, it includes information on patient characteristics, completion of health checks and outcomes achieved (as recommended by the National Institute for Clinical Excellence) for infants, children and young people with type 1 diabetes, under the age of 25, who attended paediatric diabetes units in England and Wales between 1 April 2018 and the 31 March 2019. Data are included for the seven key health checks: • Glycated Haemoglobin A1c (HbA1c) • Body Mass Index (BMI) • Thyroid • Blood pressure • Urinary albumin • Foot examination • Eye screening. Data on other health checks include: • Psychological assessment • Offering of immunisation against influenza • Advice about managing diabetes (‘sick-day rules’) • Using (or trained to use) blood ketone testing strips and a meter • Cholesterol • Additional dietetic support Data are included for health checks at diagnosis • Screening for autoimmune disease (coeliac and thyroid disease) • Provision of Level 3 carbohydrate-counting education Data on outcomes of care include: • HbA1c target measurements • Small vessel (microvascular) disease • Large vessel (macrovascular) disease • Autoimmune disease (coeliac and thyroid disease) The data were first published in 2020 alongside the National Paediatric Diabetes Audit Report 2018-2019 Data suppressed due to small numbers (

Ecuador Consumer Price Index (CPI): Health: ME: PP: Drugs Used for Diabetes data was reported at 97.764 2014=100 in Oct 2018. This records a decrease from the previous number of 98.324 2014=100 for Sep 2018. Ecuador Consumer Price Index (CPI): Health: ME: PP: Drugs Used for Diabetes data is updated monthly, averaging 99.099 2014=100 from Jan 2015 (Median) to Oct 2018, with 46 observations. The data reached an all-time high of 100.552 2014=100 in Jan 2017 and a record low of 97.764 2014=100 in Oct 2018. Ecuador Consumer Price Index (CPI): Health: ME: PP: Drugs Used for Diabetes data remains active status in CEIC and is reported by National Institute of Statistics and Census. The data is categorized under Global Database’s Ecuador – Table EC.I008: Consumer Price Index: 2014=100: Health.